Oral Estradiol Seasonal Use Considerations: A Clinical Guide

Does the dose change with the seasons?

No. The oral estradiol label gives no seasonal directions. It sets a usual initial range of 1 to 2 mg daily, adjusted as needed to control symptoms, with cyclic administration (for example 3 weeks on, 1 week off) and the minimal effective maintenance dose determined by titration [1]. Reevaluation is periodic as clinically appropriate, for example at 3- to 6-month intervals, and the label separately recommends attempts to taper or discontinue at 3- to 6-month intervals [1]. For a postmenopausal woman with a uterus, the label says a progestin should also be started to reduce endometrial cancer risk [1].

In a 12-week randomized, double-masked, placebo-controlled trial of 333 menopausal women, every oral 17beta-estradiol dose except 0.25 mg was significantly better than placebo at week 12 for reducing moderate to severe hot flushes, and the authors concluded that 1 mg appeared to be the most useful initial dose [2].

CYP3A4 interactions matter whenever they start

Estrogens are metabolized partly by CYP3A4. Inducers such as St John's wort, phenobarbital, carbamazepine and rifampin may lower estrogen plasma concentrations, possibly reducing effect or changing the uterine bleeding pattern. Inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise concentrations and cause side effects [1][3].

One randomized trial in 18 women using a low-dose oral contraceptive found that St John's wort 300 mg twice or three times daily increased intracyclic bleeding but left ethinyl estradiol AUC and peak concentration unchanged; the fall was in the progestin metabolite 3-ketodesogestrel, down 43.9 percent with twice-daily dosing [4]. That trial measured a contraceptive, not oral estradiol tablets.

Clot risk and long periods of immobility

The label says estrogens should be discontinued, if feasible, at least 4 to 6 weeks before surgery of a type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization [1].

In the French ESTHER case-control study (observational; 271 first VTE cases, 610 matched controls), current oral estrogen users had an adjusted odds ratio for VTE of 4.2 (95% CI 1.5 to 11.6) versus nonusers, while transdermal users were at 0.9 (0.4 to 2.1) [5]. The study covered oral estrogens as a group, not oral estradiol alone.